Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Forges Three Research, Distribution Deals Covering MALDI Biotyper Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today announced deals with the Institute of Medical Microbiology at the University of Zurich, Francisco Soria Melguizo, and Viollier covering the MALDI Biotyper.

The collaboration with IMM focuses on the field of coryneform bacteria, actinomycetes, fastidious gram negative bacteria, and molds. The institute, which is the Swiss national reference center for mycobacteria, is using the MALDI Biotyper as its next-generation, rapid microbial identification system.

IMM has developed its own algorithms and workflows for identification and antibiotics susceptibility testing, or AST. Its AST approaches are based primarily on Kirby-Bauer testing methods, which are now applied in combination with MALDI-TOF-based identification technology.

IMM microbiologists have designed a study for the validation of analytical performance of the MALDI Biotyper against its own molecular-characterized strain collection, and based on the results, the MALDI Biotyper reference library will be extended, improving its identification performance, Bruker said.

The company also amended an exclusive distribution agreement with Francisco Foria Melguizo to include Portugal. The two companies have had a deal since May 2009 for distribution of the MALDI Biotyper in Spain. Francisco Soria Melguizo has placed about 20 instruments in microbiology laboratories of key opinion leaders there, and recently placed the first MALDI Biotyper in Portugal, said Bruker.

Lastly, Bruker and diagnostic laboratory Viollier have extended their agreement for use of the MALDI Biotyper. Viollier, a Swiss diagnostic laboratory, has used the instrument for more than two years.

Financial and other terms of the three deals were not disclosed.

The MALDI Biotyper is for research-use only in the US, but Bruker has plans to submit an application to the US Food and Drug Administration for regulatory approval of the platform.